Entry into a Material Definitive Agreement

Business Context and Reporting Period

This Form 8-K is a current report filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp) on November 20, 2014. The filing details the consummation of an "Offer to Amend and Exercise" regarding outstanding warrants to purchase common stock, originally issued in private placement financings between January and February 2014.

Key Financial Metrics and Capital Structure

  • Gross Proceeds: Approximately $22.8 million generated from the amendment and exercise of warrants.
  • Warrants Exercised: 22,755,500 warrants were tendered and exercised, representing approximately 75% of the outstanding Original Warrants.
  • Exercise Price Adjustment: The exercise price for participating warrants was reduced from $2.00 to $1.00 per share.
  • Post-Transaction Share Count: 101,501,056 shares of common stock issued and outstanding (excluding options and remaining warrants).
  • Remaining Dilution: Outstanding options to purchase 10,829,484 shares and outstanding warrants to purchase 13,795,863 shares.

Material Changes and Agreements

The filing reports a material definitive agreement involving the amendment of warrant terms. Key changes include:

  • Lock-Up Period: Shares issued upon exercise are subject to a 50-day lock-up period following the expiration date (November 20, 2014), restricting sales, short sales, and pledges without prior written consent.
  • Anti-Dilution Removal: Price-based anti-dilution provisions were removed from the Original Warrants, Bridge Warrants, and Agent Warrants (collectively the "2014 Warrants"), rendering them of no further force or effect as of November 20, 2014.
  • Regulatory Status: The issuance of shares was exempt from registration under Rule 506 of Regulation D, with all holders representing they are accredited investors.

Outlook, Risks, and Management Commentary

Management issued a press release on November 24, 2014, regarding the transaction (incorporated by reference). The filing does not provide specific forward-looking guidance, revenue projections, or liquidity analysis beyond the immediate capital raise. The primary risk noted is the temporary restriction on the sale of newly issued shares during the 50-day lock-up period.

Investor Verification Checklist

  • Verify the final share count and dilution impact post-lock-up period expiration.
  • Confirm the utilization of the $22.8 million in gross proceeds (e.g., working capital vs. debt repayment).
  • Review the remaining 13,795,863 outstanding warrants to understand future dilution potential.
  • Check for any subsequent filings regarding the release of shares from the 50-day lock-up.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.